Divi's Laboratories Stock Touches New 52-Week High, Gains 5.72% Over the Week
Key Takeaways
- •Divi's Laboratories shares touched a new 52-week high during trading on August 28, 2026.
- •The stock was trading above a resistance level in the live session.
- •The scrip had gained 5.72% on a weekly basis, according to the live updates.
- •The Economic Times liveblog provided intraday coverage of the stock's price movement and performance.
Divi's Laboratories shares were trading strong above resistance and touched a new 52-week high during the session on August 28, 2026, according to The Economic Times Markets liveblog tracking the stock.
The live updates, which were published from the morning of August 28, also reported that the scrip had recorded a weekly gain of 5.72%. Over the course of the session, the liveblog covered the company's current price updates, overall stock performance, daily performance review, price movement analysis, and stock details, alongside related news on the counter.
About Divi's Laboratories
Divi's Laboratories Limited is an India-based pharmaceutical company headquartered in Hyderabad, Telangana. Established in 1990, the company is one of the country's major producers of active pharmaceutical ingredients (APIs), advanced intermediates, and nutraceutical ingredients, and it also provides custom synthesis services to large global pharmaceutical and generic drug makers. It is widely counted among the larger merchant producers of APIs globally, and it operates manufacturing facilities in and around Hyderabad and Visakhapatnam.
The company's shares are listed on the National Stock Exchange of India (NSE) and the BSE, where the stock trades under the symbol DIVISLAB. Divi's Laboratories is also a constituent of the Nifty 50 index, the benchmark index of the NSE, which makes the stock a holding in index funds and exchange-traded products that track the benchmark.
The company operates in a sector where India holds a leading global position: the country is among the world's largest producers of generic medicines by volume, and its API industry supplies formulators across regulated and emerging markets. The Indian government has also moved to reduce dependence on imported raw materials, introducing production-linked incentive schemes for APIs and bulk drug parks in 2020 to strengthen domestic manufacturing.
Live Coverage Details
The Economic Times liveblog was dedicated to intraday coverage of Divi's Laboratories' share price movement on August 28, 2026. Its updates indicated that the stock was holding above a resistance level, marking a new 52-week high and extending its weekly performance to a 5.72% gain. Readers can follow the original, continuously updated coverage on The Economic Times liveblog.
